Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTIVE ADOPTIVE IMMUNOTHERAPY BY T-LAK CELLS RETARGETED WITH BACTERIAL SUPERANTIGEN-CONJUGATED ANTIBODY TO MUC1 IN XENOGRAFTED SEVERE COMBINED IMMUNODEFICIENT MICE
Autore:
SHINODA M; KUDO T; SUZUKI M; KATAYOSE Y; SAKURAI N; SAEKI H; KODAMA H; FUKUHARA K; IMAI K; HINODA Y; MATSUNO S;
Indirizzi:
TOHOKU UNIV,CELL RESOURCE CTR BIOMED RES,INST DEV AGING & CANC,AOBA KU,4-1 SEIRYOMACHI SENDAI MIYAGI 9808575 JAPAN TOHOKU UNIV,CELL RESOURCE CTR BIOMED RES,INST DEV AGING & CANC,AOBA KU SENDAI MIYAGI 9808575 JAPAN TOHOKU UNIV,SCH MED,DEPT SURG 1 SENDAI MIYAGI 9808575 JAPAN SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED,CHUO KU SAPPORO HOKKAIDO 060006 JAPAN
Titolo Testata:
Cancer research
fascicolo: 13, volume: 58, anno: 1998,
pagine: 2838 - 2843
SICI:
0008-5472(1998)58:13<2838:EAIBTC>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
BILE-DUCT CARCINOMA; STAPHYLOCOCCAL-ENTEROTOXIN-B; CANCER-ASSOCIATED ANTIGEN; ACTIVATED KILLER CELLS; IN-VIVO; BISPECIFIC ANTIBODIES; TUMOR-IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES; GROWTH;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
M. Shinoda et al., "EFFECTIVE ADOPTIVE IMMUNOTHERAPY BY T-LAK CELLS RETARGETED WITH BACTERIAL SUPERANTIGEN-CONJUGATED ANTIBODY TO MUC1 IN XENOGRAFTED SEVERE COMBINED IMMUNODEFICIENT MICE", Cancer research, 58(13), 1998, pp. 2838-2843

Abstract

To reinforce cytotoxic activity and the targeting ability of lymphokine-activated killer cells with a T-cell phenotype (T-LAK) for adoptiveimmunotherapy against human bile duct carcinoma (BDC), staphylococcalenterotoxin A (SEA) was conjugated chemically with MUSE11 monoclonal antibody (MUSE11 mAb), directed to the MUC1 antigen, using N-succinimidyl 3-(2-pyridyldithio) propionate and 2-iminothiolane HCl. Both SEA-conjugated MUSE11 mAb (SEA-MUSE11) and the F(ab')(2) of MUSE11 mAb (SEA-F(ab')(2)) showed significant enhancement of T-LAK cell tumor neutralization for MUC1 positive-target tumor cells, even with a concentration of 0.01 mu g/ml at an E:T ratio of 5:1 in vitro, In this in vitro test, MUC1-positive BDC cells were observed to attach to surrounding T-LAK cells in the presence of SEA-MUSE11 or SEA-F(ab')(2). Remarkable tumor growth inhibition was observed in BDC-grafted severe combined immunodeficient mice to which 2 x 10(7) T-LAK cells preincubated with 2 mug of SEA-MUSE11 or SEA-F(ab')(2), together with recombinant interleukin 2 (500 IU), were administered i.v. for 4 consecutive days, when tumor size was 5 mm in diameter. These results point to a promising adoptive immunotherapy for patients with BDC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 01:03:09